: Mirati Therapeutics started at buy with $202 stock price target at Stifel Nicolaus

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Mirati Therapeutics Inc.

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm’s products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply